Topic: erectile dysfunction
Sales of Lilly's Cialis are set to fall from $2.3 billion a year to $55 million, pressuring the company to forge new lucrative markets.
Pfizer’s debut ad campaign for OTC Viagra in the U.K. use comparisons to highlight the relatively commonplace incidence of erectile dysfunction with print and out-of-home ads that began last week as the drug hit pharmacy shelves.
Viagra Connect, the Pfizer OTC name for its blockbuster erectile dysfunction drug, has been approved for sale in the U.K.
Is it the end of a controversial era? Erectile dysfunction ads will no longer be seen during televised NFL football games, according to a new report.
Sanofi has seen enough of ED med Stendra, and it's walking away from its marketing partnership with maker Vivus.
Pfizer is looking to reclassify Viagra (sildenafil) as a pharmacy medicine in the U.K., almost a decade after its first OTC request.
Eli Lilly suffered the failure of its long-anticipated Alzheimer’s compound solanezumab and faced falling demand for key blockbusters last year. Nevertheless, Lilly handed Lechleiter a big payout.
Endo Pharmaceuticals is recalling a self-injected erectile dysfunction drug that could become contaminated.
Eli Lilly’s erectile dysfunction med Cialis not only topped our list of exclusivity losses ranked by 2016 sales. It's also expected to post the biggest decline through 2022.
Among the many meds that’ll lose patent protection in the U.S. this year are 10 drugs that each contribute in a big way for top drugmakers. Eli Lilly, Pfizer, Takeda, Bristol-Myers Squibb and Gilead Sciences are set to hit the patent cliff this year with some of their respective big sellers.